Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
AstraZeneca
Janssen Research & Development, LLC
Bristol-Myers Squibb
Ipsen
Astellas Pharma Inc
M.D. Anderson Cancer Center
Astellas Pharma Inc
Astellas Pharma Inc
Astellas Pharma Inc
Indiana University
RECORDATI GROUP
Beth Israel Deaconess Medical Center
University of Missouri-Columbia
Pfizer
Northwestern University
Bristol-Myers Squibb
Bristol-Myers Squibb
Sanofi
Novartis
University of Florida
Ipsen
Bristol-Myers Squibb
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Johns Hopkins University
Stony Brook University
Novartis
Chesapeake Urology Research Associates
UConn Health
Astellas Pharma Inc
University of Kansas Medical Center
Johns Hopkins University
The University of Texas Health Science Center at San Antonio
Novartis
Medical University of Warsaw
GlaxoSmithKline
GlaxoSmithKline
American Medical Systems
Fox Chase Cancer Center
Advanced Research Network
Watson Pharmaceuticals
Pfizer
M.D. Anderson Cancer Center
Astellas Pharma Inc